Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-2
|
pubmed:dateCreated |
1998-10-9
|
pubmed:abstractText |
Epstein-Barr virus (EBV) has been detected in the large majority of HIV-related primary central nervous system lymphomas (PCNSL) suggesting a pathogenetic role of the virus. Unlike HIV-related PCNSL, conflicting data exist with regard to the presence of EBV in non immunodeficiency-related (sporadic) PCNSL. For this reason, a population based material of 41 sporadic PCNSL was analysed for the presence of EBV genome (EBER, BHLF) using RNA in situ hybridisation (RISH). Furthermore, the expression of the gene products of the bcl-2 oncogene and the p53 tumor suppressor gene and the tumor growth fraction reactive with the monoclonal antibody Ki-67 have been evaluated. All cases but two were EBV genome negative. In the two positive cases less than 5% of tumor cells showed EBER positivity. In contrast, more than 75% of cells morphologically belonging to the tumor-cell population stained positively for EBER in two cases of HIV related PCNSL. Immunostaining for the bcl-2 oncoprotein was positive in 28 (72%) of 39 cases examined. In most cases more than 75% of tumor cells showed cytoplasmic expression. Of 37 cases investigated for p53 expression, 21 (57%) stained positively. However, in the large majority of positive cases less than 10% of the neoplastic cells stained. The percentage of Ki-67 positive cells ranged between 10% and 80% with a mean of 50%. The expression of the p53 and bcl-2 oncoproteins and the growth fraction did not have any prognostic impact. We conclude that the EBV genome is rarely detected in sporadic PCNSL, indicating that a pathogenetic role of EBV is unlikely. Like extracerebral B-cell lymphomas a large fraction of PCNSL expresses the p53 and bcl-2 oncoproteins, a feature, however, which does not seem to have prognostic implications.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1042-8194
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
30
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
131-42
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9669683-Cell Division,
pubmed-meshheading:9669683-Central Nervous System Neoplasms,
pubmed-meshheading:9669683-Denmark,
pubmed-meshheading:9669683-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:9669683-Genes, bcl-2,
pubmed-meshheading:9669683-Genes, p53,
pubmed-meshheading:9669683-Genome, Viral,
pubmed-meshheading:9669683-Herpesvirus 4, Human,
pubmed-meshheading:9669683-Humans,
pubmed-meshheading:9669683-Immunocompetence,
pubmed-meshheading:9669683-Ki-67 Antigen,
pubmed-meshheading:9669683-Lymphoma,
pubmed-meshheading:9669683-Registries,
pubmed-meshheading:9669683-Retrospective Studies,
pubmed-meshheading:9669683-Survival Rate
|
pubmed:year |
1998
|
pubmed:articleTitle |
Primary central nervous system lymphomas in immunocompetent individuals: histology, Epstein-Barr virus genome, Ki-67 proliferation index, p53 and bcl-2 gene expression.
|
pubmed:affiliation |
Dept. of Haematology, Aalborg Hospital, Denmark.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|